A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)
Besse, B. Paz-Ares, L. G. Peters, S. Cappuzzo, F. Reck, M. Calles, A. Califano, Raffaele Lopez-Vilarino, J. A. Veramendi, S. Kahatt, C. M.
Besse, B.
Paz-Ares, L. G.
Peters, S.
Cappuzzo, F.
Reck, M.
Calles, A.
Califano, Raffaele
Lopez-Vilarino, J. A.
Veramendi, S.
Kahatt, C. M.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Besse B, Paz-Ares LG, Peters S, Cappuzzo F, Reck M, Calles A, et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005484.